News and Trends

Hansa Biopharma has granted an exclusive license to Sarepta Therapeutics for developing and promoting a pretreatment aimed to make a gene therapy to treat muscular dystrophy available to people that are naturally resistant to the treatment.  Gene therapy can be used to treat genetic conditions by delivering a healthy copy of the faulty gene using […]

Microfluidics company DigiBio and food security specialist SwissDeCode have joined forces to automate onsite milk testing and track down fraudulent adulterants such as vegetable ingredients or milk from different species.  Milk is the second most likely food at risk of adulteration after olive oil. This fraudulent practice can mislead consumers at best, and cause major […]

The Swiss firm CRISPR Therapeutics has priced a public offering on the Nasdaq Global Market at around €400M, which it will use to develop therapies based on the gene editing tool CRISPR/Cas9 for genetic disorders and cancer. This fundraise is the second-highest global share offering from a European biotech so far this year after the […]

UK biotech Freeline Therapeutics has extended its Series C round to take its gene therapy for hemophilia B to a pivotal trial, while hinting at the possibility of an IPO in the US later this year. This final closing adds an additional €70M to a €36M Series C investment by London-based VC Syncona in December […]

The regenerative medicine startup Cutiss has raised €18.8M (CHF 20M) to commercialize its personalized skin graft treatment for burn patients in Switzerland and the European Union around 2022. This is the final closing of a Series B round announced earlier this month. The lead investor in the oversubscribed round was the Swiss firm Gisev Family […]